GSK moved quickly to secure a trispecific T-cell engager from Chimagen Biosciences, committing up to $750 million to advance a multiple myeloma program. The asset is designed as a tri-specific approach—aimed at engaging three targets—positioned by GSK as potentially offering advantages over existing bispecific T-cell engagers. The deal places an additional multiple myeloma modality in the spotlight at a time when T-cell engagers remain among the highest-intensity areas of Big Pharma R&D and partnering. It also reinforces GSK’s strategy of using targeted immuno-oncology licensing to build early clinical pipelines with differentiated mechanisms. For Chimagen, the funding and global rights agreement moves its Phase 1-ready program closer to first-in-human dosing and expands the company’s pathway from discovery through clinical execution.